Clinical trials
Dilated Cardiomyopathy clinical trials
Below are recruiting dilated cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 54 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04990297Recruiting
MRI test to better predict risk in dilated heart muscle
This trial uses a heart MRI to measure details in people with dilated cardiomyopathy and reduced pumping strength. It aims to use these MRI findings to better predict your future heart risk and guide care.
Beijing, Beijing MunicipalityAges Any age - NCT02445534Recruiting
Registry for cell therapy in non-ischemic dilated heart muscle disease
This is a research registry that follows people with non-ischemic dilated cardiomyopathy (a weakened heart muscle) who are already on the right medications. It helps doctors better understand how cell-based therapy and related care affect heart function over time.
LjubljanaAges 18–65 - NCT07527715Recruiting
Heart MRI Study for Dilated Heart Muscle Disease
This research uses cardiac MRI scans and patient data to better predict outcomes in people with dilated cardiomyopathy—a condition where the heart's main pumping chamber becomes enlarged and weakened. Participating could help doctors improve how they care for similar patients in the future.
Jinan, ShandongAges 18 years+ - NCT07516288RecruitingPhase 1
Second CAR-DC Cell Infusion for Advanced Heart Failure
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
Hangzhou, Zhejiang / 浙江Ages 18–75 - NCT07426419RecruitingPhase 1/Phase 2
Gene therapy for heart failure caused by BAG3 mutation
This trial tests an experimental gene therapy (AFTX-201) designed to address the genetic cause of heart failure in people with a specific BAG3 gene mutation. It aims to improve heart function and reduce symptoms.
Miami, FloridaAges 18–70 - NCT07420907Recruiting
Tracking heart health over time
This study uses a wearable patch to monitor heart-related signs in people with heart conditions. It aims to learn more about how these conditions progress, which could help improve future care.
Chicago, IllinoisAges 18 years+ - NCT07293338Recruiting
Heart muscle blood flow study for dilated cardiomyopathy
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
Hangzhou, ZhejiangAges 18 years+ - NCT07241104RecruitingPhase 1
Study of a new drug for dilated cardiomyopathy with a specific genetic change
This trial tests an experimental drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic mutation (R14del in the PLN gene). The goal is to see if the drug can improve heart function and symptoms.
AmsterdamAges 18–80 - NCT06741995Recruiting
Testing antibodies to predict heart muscle disease progression
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
Wuhan, HubeiAges 18–75 - NCT07137338RecruitingPhase 1
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
San Diego, CaliforniaAges 18–65 - NCT06902896RecruitingPhase 1/Phase 2
FAP iCDC therapy for advanced heart failure from dilated cardiomyopathy
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
Hangzhou, ZhejiangAges 18–75 - NCT02432092Recruiting
Genetic testing for heart muscle disease in children and families
This study looks at genetic (DNA) changes that may cause cardiomyopathy, a disease where the heart muscle is weakened. It may help families understand possible causes and inform future care.
Indianapolis, IndianaAges Any age - NCT06464588RecruitingPhase 1
Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Atlanta, GeorgiaAges 4–40 - NCT03527342Enrolling by invitation
Sahlgrenska heart muscle disease study
This study focuses on people with certain “heart muscle” conditions (cardiomyopathies) to better understand them and guide care. If you have one of these specific diagnoses and are an adult, you may be able to take part.
GothenburgAges 18–99 - NCT05750147Recruiting
Study for cardiomyopathy linked to family or genes
This study looks at people with cardiomyopathy (or related heart muscle conditions) and those who may be at risk because of family history or genetic test results. It may help researchers better understand who is likely to develop the condition and how best to monitor or support them.
LondonAges Any age - NCT07771465RecruitingPhase 3
Long-term safety of danicamtiv for genetic dilated cardiomyopathy
This study checks the long-term safety and effectiveness of the drug danicamtiv in people with a genetic form of dilated cardiomyopathy, a condition where the heart muscle becomes weak and enlarged. If you've already completed the earlier DAN-301 study, this trial continues to monitor you while you keep taking the medication.
Birmingham, AlabamaAges 18 years+ - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Birmingham, AlabamaAges 18 years+ - NCT06607471Recruiting
Study on non-ischemic heart muscle diseases
This study looks at different types of heart muscle diseases that are not caused by blocked arteries (non-ischemic cardiomyopathies). It aims to better understand how to diagnose, predict outcomes, and treat these conditions by gathering information from many patients over time.
Milan, MilanoAges 18 years+ - NCT04558723Recruiting
MRI-guided heart defibrillator placement for non-ischemic weakened hearts
This study looks at whether using a heart MRI (CMR) to guide where to place an implanted defibrillator (ICD) improves outcomes for people with a weakened heart muscle caused by non-ischemic dilated cardiomyopathy. It’s for adults who have low pumping strength and evidence of heart scarring on MRI.
Lübeck, Schleswig-HolsteinAges 18 years+ - NCT07646600Recruiting
Natural History Study of BAG3 Heart Disease in Chinese Adults
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
BeijingAges 18 years+ - NCT06730464Recruiting
Predicting dangerous heart rhythms in non-ischemic heart disease
This study uses heart MRI scans to predict who might develop dangerous heart rhythms. It's for people with certain types of non-ischemic heart disease who have already had an MRI with contrast.
Milan, ItalyAges 18 years+ - NCT07218887RecruitingPhase 1/Phase 2
Gene therapy for BAG3-related heart failure
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
Birmingham, AlabamaAges 18–70 - NCT06922851Recruiting
Protein filter therapy for dilated cardiomyopathy
This trial tests a protein filtering treatment (immunoadsorption) for people with dilated cardiomyopathy who have a specific antibody linked to heart damage. It aims to see if removing these antibodies can improve heart function.
Wuhan, HubeiAges 18–75 - NCT03479580Recruiting
Registry for coronary and small-vessel heart disease in cardiomyopathy
This study enrolls people with certain types of heart muscle diseases to learn how blocked heart arteries and tiny blood vessels affect symptoms and outcomes. It may help researchers better understand these conditions and improve future care.
La TroncheAges 18–100
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for dilated cardiomyopathy?
- Yes. Clin2 currently lists 54 recruiting dilated cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a dilated cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a dilated cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.